Thus our results demonstrate that elevated NHE1 expression in glioma and tumor-associated macrophages (TAMs) are important for GBM progression and inhibition of NHE1 function represents a novel strategy to improve the efficacy of glioma therapies. Here, SLC9A1 is linked to glioblastoma.